ZJYL (Jin Medical International) Beneish M-Score: -2.44 (As of Jul. 17, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ZJYL Jin Medical International Ltd ZJYL
63 GF Score
Price $1.94
GF Value $14.58
Valuation Significantly Undervalued
! 7 Warning Signs
View Full Analysis

What is Jin Medical International Beneish M-Score?

Jin Medical International ZJYL 63 Beneish M-Score is -2.44 as of Jul. 17, 2026. GuruFocus rates ZJYL with a GF Score™ of 63/100 and a GF Value™ of $14.58 (Significantly Undervalued). The stock has 7 warning signs investors should review. Among 763 Medical Devices & Instruments companies, Jin Medical International ranks worse than 62.25% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.44 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Jin Medical International's Beneish M-Score or its related term are showing as below:

ZJYL' s Beneish M-Score Range Over the Past 10 Years
Min: -2.53   Med: -2.15   Max: -1.47
Current: -2.44

During the past 6 years, the highest Beneish M-Score of Jin Medical International was -1.47. The lowest was -2.53. And the median was -2.15.


Jin Medical International Beneish M-Score Historical Data

* Premium members only.

The historical data trend for Jin Medical International's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Jin Medical International Beneish M-Score Chart

Jin Medical International Annual Data
Trend Sep20 Sep21 Sep22 Sep23 Sep24 Sep25
Beneish M-Score
Get a 7-Day Free Trial 0.00 -2.53 -1.85 -1.47 -2.44

Jin Medical International Semi-Annual Data
Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only -1.85 0.00 -1.47 0.00 -2.44

ZJYL vs RVP, CUPR, BNGO: Beneish M-Score Comparison

For the Medical Instruments & Supplies subindustry, Jin Medical International's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Jin Medical International Beneish M-Score vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Jin Medical International's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Jin Medical International's Beneish M-Score falls into.


ZJYL
63GF Score
Jin Medical International Ltd ZJYL
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Jin Medical International Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Jin Medical International for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.8807+0.528 * 1.3837+0.404 * 0.8413+0.892 * 0.8802+0.115 * 3.9831
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 1.0091+4.679 * -0.035827-0.327 * 1.184
=-2.44

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Sep25) TTM:Last Year (Sep24) TTM:
Total Receivables was $6.80 Mil.
Revenue was $20.69 Mil.
Gross Profit was $6.05 Mil.
Total Current Assets was $44.14 Mil.
Total Assets was $53.37 Mil.
Property, Plant and Equipment(Net PPE) was $7.98 Mil.
Depreciation, Depletion and Amortization(DDA) was $0.35 Mil.
Selling, General, & Admin. Expense(SGA) was $3.88 Mil.
Total Current Liabilities was $23.80 Mil.
Long-Term Debt & Capital Lease Obligation was $0.00 Mil.
Net Income was $1.19 Mil.
Gross Profit was $0.20 Mil.
Cash Flow from Operations was $2.90 Mil.
Total Receivables was $8.78 Mil.
Revenue was $23.50 Mil.
Gross Profit was $9.50 Mil.
Total Current Assets was $42.82 Mil.
Total Assets was $45.80 Mil.
Property, Plant and Equipment(Net PPE) was $1.72 Mil.
Depreciation, Depletion and Amortization(DDA) was $0.35 Mil.
Selling, General, & Admin. Expense(SGA) was $4.37 Mil.
Total Current Liabilities was $17.15 Mil.
Long-Term Debt & Capital Lease Obligation was $0.10 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(6.803 / 20.687) / (8.776 / 23.502)
=0.328854 / 0.373415
=0.8807

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(9.503 / 23.502) / (6.045 / 20.687)
=0.404349 / 0.292213
=1.3837

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (44.143 + 7.981) / 53.368) / (1 - (42.816 + 1.716) / 45.801)
=0.02331 / 0.027707
=0.8413

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=20.687 / 23.502
=0.8802

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(0.346 / (0.346 + 1.716)) / (0.351 / (0.351 + 7.981))
=0.167798 / 0.042127
=3.9831

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(3.879 / 20.687) / (4.367 / 23.502)
=0.187509 / 0.185814
=1.0091

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((0 + 23.796) / 53.368) / ((0.096 + 17.152) / 45.801)
=0.445885 / 0.376586
=1.184

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(1.191 - 0.199 - 2.904) / 53.368
=-0.035827

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Jin Medical International has a M-score of -2.44 suggests that the company is unlikely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of -2.44 mean?
Jin Medical International (ZJYL) has a Beneish M-Score of -2.44 as of Jul. 17, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Jin Medical International and its competitors. According to the industry distribution chart, Jin Medical International ranks #475 out of 763 companies in the Medical Devices & Instruments industry, placing it in the top 62.3%.
Is Jin Medical International's Beneish M-Score too high?
Jin Medical International's current Beneish M-Score is -2.44. Based on the distribution chart, Jin Medical International ranks #475 out of 763 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Jin Medical International has a GF Score™ of 63/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Jin Medical International's Beneish M-Score compare to RVP and CUPR?
According to the Medical Devices & Instruments industry distribution chart, Jin Medical International ranks #475 out of 763 companies for Beneish M-Score. This places Jin Medical International in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Medical Devices & Instruments company?
A good Beneish M-Score depends on the Medical Devices & Instruments industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Jin Medical International and its competitors. Jin Medical International's current Beneish M-Score is -2.44. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jin Medical International stock overvalued right now?
Based on GuruFocus' analysis, Jin Medical International (ZJYL) is currently considered Significantly Undervalued. The stock's GF Value™ is $14.58, compared to a current price of $1.94 — trading 86.7% below its estimated fair value. The current Beneish M-Score is -2.44. Jin Medical International's overall GF Score™ is 63/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For Jin Medical International (ZJYL), the current Beneish M-Score is -2.44 as of Jul. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Jin Medical International (ZJYL) Overvalued in 2026?

Based on GuruFocus' analysis, Jin Medical International stock appears to be undervalued. The current stock price of $1.94 is trading 86.7% below its estimated GF Value™ of $14.58. GuruFocus considers Jin Medical International to be Significantly Undervalued.

Key valuation signals for ZJYL:

  • Beneish M-Score: -2.44
  • GF Value™: $14.58 vs. price of $1.94 (86.7% below fair value)
  • GF Score™: 63/100 with 7 warning signs

No single metric tells the full story. See the ZJYL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Jin Medical International Business Description

Address No. 33 Lingxiang Road, Wujin District, Jiangsu Province, Changzhou, CHN
Jin Medical International Ltd, along with its subsidiaries, mainly offers rehabilitation equipment. It is engaged in the design, development, manufacturing, and sales of wheelchairs and other assistive living aid products for use by people with disabilities or impaired mobility. The group's product offering includes wheelchairs and wheelchair components, oxygen concentrators, bathing machines, respiratory and walking aids, oxygen chambers, beauty instruments, and nano products, among others. Wheelchairs are currently its key revenue-generating product. The products are sold to dealers in Japan and China, and to some extent to dealers located in the United States, Canada, Australia, Korea, Israel, Singapore, and other regions. Geographically, the group generates maximum revenue from Japan.
63GF Score

Get the complete analysis for ZJYL

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.94
Price
$14.58
GF Value